Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Analysis by Product & Application The global central nervous system biomarkers market will witness a robust CAGR of 9.0%, valued at $4 billion in 2021, expected to appreciate and reach $8.7 billion by 2030, confirms Strategic Market Research. North America is projected to have the most significant market share throughout the projection period. The word "biomarker" refers to a wide variety of measurements that apprehend what is going inside a cell or organism at any instant. Biomarkers are objective medical signals (as opposed to patient-reported symptoms) that are used to assess the existence or progression of illness and the treatment's effects. Molecular, histologic, radiographic, and physiological properties can all be found in biomarkers. Blood pressure & heart rate are examples of biomarkers, along with simple metabolic investigations, X-ray results and detailed histologic and genetic examinations of blood and other tissues. The National Library of Medicine reported that one in 200,000 individuals in the United States is diagnosed with syndrome a each year. Moreover, in 2020, 12,000 individuals died from syndrome C globally. Biomarkers are measurable indicators of how a person feels and behaves. Biomarkers are now so widely used in scientific and clinical research and clinical practice that their inclusion as main endpoints in clinical trials is nearly unquestioned. This usage is legitimate and suitable in the case of specific biomarkers that have been adequately described and consistently proved to correctly predict important clinical outcomes across various treatments and demographics. New technology breakthroughs and their rising Application in detecting neurodegenerative conditions are two crucial reasons for boosting the CNS biomarkers market. Market Drivers - Increase in Obesity Leading to Neurological Illnesses, Technological Advancement, and Successful Implementation of New Findings High-throughput sequencing of the human genome (MicroRNA, Extracellular RNA) and its encoded proteins has enabled systematic investigation of human illness. These technologies are proven to be a more reliable way of discovering the biological foundation of genetically complex neurological diseases. According to WHO, in developed countries, genetic illnesses and congenital anomalies affect roughly 2% to 5% of all newborns accounting for up to 30% of paediatric hospital admissions and responsible for about half of all children fatalities. Furthermore, advances in genomics and proteomics over the last decade have increased understanding of genetic regulatory networks linked to (central nervous system) CNS biomarkers. Moreover, Biomarkers will help drug development and evaluation of target engagement and medication efficacy in neurological illnesses due to traumatic brain injury if included in drug research and clinical trials. Traumatic Brain Injury (TBI) affects around 2.8 million individuals in the United States each year, with around 280,000 requiring hospitalizations, according to the BIAA. 50,000 of these injuries result in death. Furthermore, according to the CDC, there were 176 fatalities per day in the United States due to TBI in 2020, with people over the age of 75 accounting for 28% of the mortality rates. The growing prevalence of neurological diseases, with stroke being the second largest cause of death, according to a WHO study released in December 2020, is likely to fuel the expansion of the CNS biomarkers market throughout the forecast period. Furthermore, obesity is becoming one of the most detrimental public health problems fueling the growth of the worldwide Central Nervous System (CNS) biomarker market. According to the World Obesity Federation, one billion people worldwide, including one in every five women and one in every seven men, will be obese by 2030. Type 2 diabetes affects 463 million persons worldwide between the ages of 18 and 79, as reported by the International Diabetes Federation in 2020. This number is expected to reach 700 million by 2045. These figures are exceptionally high in developing countries, and the incidence is expected to worsen with time. Market Restraints - High Validation Cost and Unfavourable Reimbursement Costs The central nervous system biomarkers market may be hampered by high validation costs, such as sample collection and storage and unfavourable reimbursement status for biomarker research and discovery. Opportunities - Rising Concerns about Neurological Illnesses and Improved R&D According to Global Cancer Observatory, there were 2,281,658 cancer cases diagnosed and 612,390 cancer-related deaths reported in the US in 2020. The National Institute of Neurological Disorders & Stroke is particularly interested in methods that might speed up identifying and validating reliable biomarkers. The market is likely to rise throughout the forecasted period, owing to increasing concerns about neurological illnesses and increased investment in the R&D and new CNS biomarkers patents to get the approval of FDA-best biomarkers. The market will rise when new biomarkers such as neuroscience and neurological biomarkers for identifying and treating Alzheimer's disease are developed and patented. Increased longevity has led to an increase in the older population, resulting in a higher frequency of dementia. In one of its reports, Johns Hopkins School of Medicine reported that Alzheimer's disease is the most prevalent form of dementia, affecting 5.2 million Americans above the age of 65 and thousands of individuals younger than 65 got early-onset Alzheimer's. Alzheimer's disease is expected to affect 131 million people by 2050. Market Analysis Of Different Segments Covered in the Report Based on Type: Safety Biomarker Efficacy Biomarker Validation Biomarker Other Based on Application: Drug Discovery & Development Personalized Medicine Others Based on End-User: Diagnostic Labs Hospitals& Clinics Research Centers Regional Coverage Analysis North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific Middle-East and Africa GCC South Africa Rest of the Middle East and Africa South America Brazil Argentina Rest of South America Type Analysis & Insights Based on Type, in 2020, the Safety Biomarker category held the most significant market share, and it is forecasted to be the fastest-growing market in the forecast period due to rising awareness regarding routine health exams, depression, Parkinson's disease, multiple sclerosis, and increasing utilization in the preclinical stage. According to research released by a group of pharmaceutical firms in December 2020, safety indicators were employed by 83 % of the 24 businesses questioned during the clinical trial phase. Application Analysis & Insights Based on Application, Personalized Medicine has been identified as the most promising technique for combating various disorders. The growing prevalence of brain and other nervous system malignancies is one of the primary reasons driving the market's rise. As a result, many firms are focusing their efforts on creating breakthrough medications to treat neurological illnesses. End Users Analysis & Insights Based on End users, the increased need for CNS biomarkers in Diagnostic Centres is driven by an ageing population and increased cancer incidence due to organophosphates. Biomarkers are needed to help in the detection of a variety of neurological illnesses as well as the monitoring of disease development. The need for CNS biomarkers in diagnostic labs is expected to rise as new tools for early diagnosis are developed. In the United States, in 2020, an expected 24,530 people and 3,460 children under the age of 15 were reported with a primary brain or spinal cord tumour, according to research by Cancer.net. According to the National Brain Tumor Society, roughly 85,000 additional instances of brain tumours will be there in 2021. Regional Analysis & Insights Based on Region, North America had the most significant revenue share in 2020; it is the largest market for Central Nervous systems. According to the American Cancer Society, brain malignancy will be the second most often detected cancer in children and adolescents, with 27 % and 21 % in 2021. In addition, according to the American Cancer Society, USD 23.1 million has been set aside for brain-related clinical and cancer control research in the United States as of August 2020. As a result of the previous assertions, the North American region is predicted to have the most robust market share throughout the projection period. Due to factors such as a large client base, an increasing prevalence of central nervous system illnesses, and improved healthcare infrastructure, the Asia Pacific central nervous system biomarkers market is expected to be the fastest-growing market. In addition, the region's increased research capability and improved healthcare infrastructure are likely to aid in the development of novel central nervous system biomarkers. Central Nervous System (CNS) Biomarkers Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 Market size value in 2021 USD 4 billion Revenue forecast in 2030 USD 8.7 billion Growth rate CAGR of 9.0 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2020 - 2030) Segmentation By Type, By Application, By End User, By Region By Type Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other By Application Drug Discovery & Development, Personalized Medicine, Others By End-User Diagnostic Labs, Hospitals& Clinics, Research Centers By Region North America, Middle East & Africa, Asia Pacific, Europe, and South America Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India etc. Company Usability Profiles Thermo Fisher Scientific, Merck & Co., AbaStarMDx Inc., Abiant, Inc., Avacta Group plc, Diagenetic Asa, Banyan Biomarkers, Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Siemens AG, Novartis. Pricing and purchase options Customized buying options are available to meet your exact research needs. Global Central Nervous System Biomarkers Market Competitive Landscape Analysis The competitive landscape analysis gives an overview of some prominent players operating in the market. Product innovation and continued R&D operations to create sophisticated technologies have assisted the market's growth. In the target market, there are many significant companies, and some of the market leaders are: Thermo Fisher Scientific Merck & Co. AbaStarMDx Inc. Abiant, Inc. Avacta Group plc Diagenetic Asa Banyan Biomarkers Avid Radiopharmaceuticals Inc. Acumen Pharmaceuticals Inc. Siemens AG Novartis G-Biosciences Merck KGaA Bio-Rad Laboratories, Inc. Biomeriux (Banyan Biomarkers Inc.) Recent Developments: On April 2022, the existence of an ALS biomarker in the skin of patients was discovered by researchers from the University Autnoma de Barcelona's (UAB) Neuroplasticity and Regeneration Group and the Hospital del Mar's Functional Unit for Amyotrophic Lateral Sclerosis. TDP-43 is a particular protein found outside the nucleus of patient skin cells. The presence of an increased number of cells with this mutation in the skin helps doctors forecast whether a patient has the illness and how far it has gone. On March 2022, the latest findings on lecanemab, an investigational anti-amyloid-beta (A) protofibril antibody being utilized for the treatment of early Alzheimer's disease (AD), were presented at the A Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson’s disease (AD/PDTM), March 15-20 in Barcelona, Spain, virtually. On November 2021, In the Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an experimental anti-amyloid beta (A) protofibril antibody, Eisai Co., Ltd. and Biogen Inc. made a presentation regarding examining the use of plasma-based biomarkers. The preclinical Alzheimer's disease (AD) experiment AHEAD 3-45 is the first to employ these biomarkers to diagnose AD pathology and perhaps speed up the screening process. In addition, the Alzheimer's Clinical Trial Consortium (ACTC) presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference. On August 2021, Diadem Srl, which is developing the first blood-based test for the early detection of Alzheimer's disease (AD), released the findings of a retrospective longitudinal study of its AlzoSure predictive biomarker test. Before being submitted to the Journal of Neuroscience, the paper, A structural variation of p53 (U-p53AZ) as a blood-based biomarker for the predicting the beginning of symptomatic Alzheimer’s disease, is now accessible as a medRxiv preprint. The findings show that AlzoSure Predict correctly predicts those with minimal or modest cognitive impairments who will develop highly symptomatic Alzheimer's disease up to 6 years before symptoms appear. On September 2020, Siemens Healthineers and Novartis Pharma AG signed a master partnership agreement to create, develop, and market diagnostic tests for Novartis' medicinal portfolio. The first initiative supports Novartis' MS and other neuroscience activities by encouraging the growth of a serum NFL immunoassay. Various Devices that the Market Leaders are Manufacturing Name of the Product Function Key Player 5500 W Series Genetic Analysis System Can do exome sequencing and RNA-Seq on a pay-per-lane basis. Thermo Fisher Scientific Human Cytokine Array C5 To look for chemo/cytokine expression in the conditioned media of cancer cells co-cultured with macrophages. RayBiotech Inc. Terminal Deoxynucleotidyl Transferase It is a template-independent DNA polymerase that catalyzes the addition of deoxyribonucleotides to the 3'-OH of oligodeoxyribonucleotides and single-stranded and double-stranded DNA on a repeated basis. Thermo Fisher Scientific Frequently Asked Question About This Report Name some of the leading market players? Some of the key players are: Avacta Group plc, Diagenetic Asa, Banyan Biomarkers, Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Siemens AG, etc. Which is the most dominant region of the market? North America had the most significant market share in terms of revenue in 2020 What significant factors drive the global market? New technology breakthroughs and their rising Application in detecting neurodegenerative conditions are two crucial reasons for boosting the global market. What are the Central Nervous System Biomarkers market growth? The global Central Nervous System Biomarkers market is expected to grow at a compound annual growth rate (CAGR) of 9.0 % from 2021 to 2030 to reach USD 8.7 Billion by 2030. How big is the Central Nervous System Biomarkers market? The global Central Nervous System Biomarkers market size was $ 4 Bn in 2021 and is predicted to reach $ 8.7 Bn by 2030, with a CAGR of 9.0 %. What is the valuation of the market? The global market Size will reach USD 8.7 billion by 2030. Sources https://rarediseases.info.nih.gov/about http://www.emro.who.int/emhj-volume-3-1997/volume-3-issue-1/article18.html https://www.cdc.gov/traumaticbraininjury/data/index.html https://www.aa.com.tr/en/health/diabetes-forecast-to-affect-700-million-by-2045/1644949 https://gco.iarc.fr/ 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Central Nervous System (CNS) Biomarkers Market 4.2.1 Global Market, 2020 – 2028 (USD Million) 4.3 Regional Analysis 4.3.1 Global Market, By region, 2021 - 2030 (USD Million) 4.4 By Type Analysis 4.4.1 Global Market, By Type, 2021 - 2030 (USD Million) 4.5 By End-User Analysis 4.5.1 Global Market, By End-User, 2021 - 2030 (USD Million) 4.6 Application Analysis 4.6.1 Global Market, By Application, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Safety Biomarker 7.3.1. Safety Biomarker Market, 2021 - 2030 (USD Million) 7.4. Efficacy Biomarker 7.4.1. Efficacy Biomarker Market, 2021 - 2030 (USD Million) 7.5. Validation Biomarker 7.5.1. Validation Biomarker Market, 2021 - 2030 (USD Million) 7.5. Other 7.5.1. Other Market, 2021 - 2030 (USD Million) 8. Global Market: By End-User Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Diagnostic Labs 8.3.1. Diagnostic LabsMarket, 2021 - 2030 (USD Million) 8.4. Hospitals & Clinics 8.4.1. Hospitals & Clinics Market, 2021 - 2030 (USD Million) 8.5. Research Centers 8.5.1. Research Centers Market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Drug Discovery & Development 9.3.1. Drug Discovery & DevelopmentMarket, 2021 - 2030 (USD Million) 9.4. Personalized Medicine 9.4.1. Personalized Medicine Market, 2021 - 2030 (USD Million) 9.5. Others 9.5.1. Others Market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America Market, By Type, 2021 - 2030 (USD Million) 10.1.2. North America Market, By End-User, 2021 - 2030 (USD Million) 10.1.3. North America Market, By Application, 2021 - 2030 (USD Million) 10.1.4. North America Market, By Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S. Market, By Type, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S. Market, By End-User, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S. Market, By Application, 2021 - 2030 (USD Million) 10.1.4.2.Canada 10.1.4.2.1. Canada Market, By Type, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada Market, By End-User, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada Market, By Application, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe Market, By Type, 2021 - 2030 (USD Million) 10.2.2. Europe Market, By End-User, 2021 - 2030 (USD Million) 10.2.3. Europe Market, By Application, 2021 - 2030 (USD Million) 10.2.4. Europe Market, By country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. Market, By Type, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. Market, By End-User, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. Market, By Application, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany Market, By Type, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany Market, By End-User, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany Market, By Application, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France Market, By Type, 2021 - 2030 (USD Million) 10.2.4.3.2. France Market, By End-User, 2021 - 2030 (USD Million) 10.2.4.3.3. France Market, By Application, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe Market, By Type, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe Market, By End-User, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe Market, By Application, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific Market, By Type, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific Market, By End-User, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific Market, By Application, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific Market, By country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China Market, By Type, 2021 - 2030 (USD Million) 10.3.4.1.2. China Market, By End-User, 2021 - 2030 (USD Million) 10.3.4.1.3. China Market, By Application, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India Market, By Type, 2021 - 2030 (USD Million) 10.3.4.2.2. India Market, By End-User, 2021 - 2030 (USD Million) 10.3.4.2.3. India Market, By Application, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan Market, By Type, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan Market, By End-User, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan Market, By Application, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea Market, By Type, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea Market, By End-User, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea Market, By Application, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC Market, By Type, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC Market, By End-User, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC Market, By Application, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America Market, By Type, 2021 - 2030 (USD Million) 10.4.2. Latin America Market, By End-User, 2021 - 2030 (USD Million) 10.4.3. Latin America Market, By Application, 2021 - 2030 (USD Million) 10.4.4. Latin America Market, By country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil Market, By Type, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil Market, By End-User, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil Market, By Application, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico Market, By Type, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico Market, By End-User, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico Market, By Application, 2021 - 2030 (USD Million) 10.4.4.3. Rest of the Latin America 10.4.4.3.1. Rest of the Latin America Market, By Type, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America Market, By End-User, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America Market, By Application, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA Market, By Type, 2021 - 2030 (USD Million) 10.5.2. MEA Market, By End-User, 2021 - 2030 (USD Million) 10.5.3. MEA Market, By Application, 2021 - 2030 (USD Million) 10.5.4. MEA Market, By Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 Thermo Fisher Scientific 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. ProductPortfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. MERCK & CO. 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. ABASTARMDX INC. 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. ABIANT, INC. 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. AVACTA GROUP PLC 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Diagenetic Asa 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Banyan Biomarkers 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Avid Radiopharmaceuticals Inc. 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Acumen Pharmaceuticals Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Siemens AG 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Novartis (Switzerland) 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. G-Biosciences. 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Merck KGaA 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Bio-Rad Laboratories, Inc. 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. Biomeriux (Banyan Biomarkers Inc.) 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development List of Tables (60 Tables) TABLE 1. MARKET, By Type, 2021-2030 (USD Million) TABLE 2. MARKET FOR Safety Biomarker, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Efficacy Biomarker, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Validation Biomarker, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Other, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET, By End-User, 2021-2030 (USD Million) TABLE 7. MARKET FOR Diagnostic Labs, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Hospitals & Clinics, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Research Centers, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 11. MARKET FOR Drug Discovery & Development, BY REGION, 2021-2030 (USD Million) TABLE 12. MARKET FOR Personalized Medicine, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) Nervous System (CNS) Biomarkers, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 15. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 16. NORTH AMERICA MARKET, By Type, 2021-2030 (USD Million) TABLE 17. NORTH AMERICA MARKET, By End-User, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 19. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. EUROPE MARKET, By Type, 2021-2030 (USD Million) TABLE 21. EUROPE MARKET, By End-User, 2021-2030 (USD Million) TABLE 22. EUROPE MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 23. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. ASIA-PACIFIC MARKET, By Type, 2021-2030 (USD Million) TABLE 25. ASIA-PACIFIC MARKET, By End-User, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 27. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. LAMEA MARKET, By Type, 2021-2030 (USD Million) TABLE 29. LAMEA MARKET, By End-User, 2021-2030 (USD Million) TABLE 30. LAMEA MARKET, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. Thermo Fisher Scientific: COMPANY SNAPSHOT TABLE 32. Thermo Fisher Scientific: OPERATING SEGMENTS TABLE 33. MERCK & CO.: COMPANY SNAPSHOT TABLE 34. MERCK & CO.: OPERATING SEGMENTS TABLE 35. ABASTARMDX INC. : COMPANY SNAPSHOT TABLE 36. ABASTARMDX INC. : OPERATING SEGMENTS TABLE 37. ABIANT, INC. : COMPANY SNAPSHOT TABLE 38. ABIANT, INC. : OPERATING SEGMENTS TABLE 39. AVACTA GROUP PLC: COMPANY SNAPSHOT TABLE 40. AVACTA GROUP PLC: OPERATING SEGMENTS TABLE 41. Diagenetic Asa: COMPANY SNAPSHOT TABLE 42. Diagenetic Asa: OPERATING SEGMENTS TABLE 43. Banyan Biomarkers: COMPANY SNAPSHOT TABLE 44. Banyan Biomarkers: OPERATING SEGMENTS TABLE 45. Avid Radiopharmaceuticals Inc.: COMPANY SNAPSHOT TABLE 46. Avid Radiopharmaceuticals Inc.: OPERATING SEGMENTS TABLE 47. Acumen Pharmaceuticals Inc. : COMPANY SNAPSHOT TABLE 48. Acumen Pharmaceuticals Inc. : OPERATING SEGMENTS TABLE 49. Siemens AG: COMPANY SNAPSHOT TABLE 50. Siemens AG: OPERATING SEGMENTS TABLE 51. Novartis (Switzerland): COMPANY SNAPSHOT TABLE 52. Novartis (Switzerland): OPERATING SEGMENTS TABLE 53. G-Biosciences: COMPANY SNAPSHOT TABLE 54. G-Biosciences: OPERATING SEGMENTS TABLE 55. Merck KGaA: COMPANY SNAPSHOT TABLE 56. Merck KGaA: OPERATING SEGMENTS TABLE 57. Bio-Rad Laboratories, Inc.: COMPANY SNAPSHOT TABLE 58. Bio-Rad Laboratories, Inc.: OPERATING SEGMENTS TABLE 59. Biomeriux (Banyan Biomarkers Inc.): COMPANY SNAPSHOT TABLE 60. Biomeriux (Banyan Biomarkers Inc.): OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 15 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Central Nervous System (CNS) Biomarkers, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Central Nervous System (CNS) Biomarkers, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By End-User, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Type, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Market Figure 15 Safety Biomarker to Witness Higher CAGR in Market for Type Segment during Forecast Period. Figure 16 Personalized Medicine to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 17 Diagnostic Centres to Witness Higher CAGR in Market for End-User Segment during Forecast Period. Figure 18 North America region Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview